RVMD Revolution Medicines Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
15:07
Sep 03
Sep 03
Author suggests a potential RVMD-like rally for ABVX if Crohn's succeeds.
Author suggests a potential RVMD-like rally for ABVX if Crohn's succeeds, framing it as a valuation concern rather than a personal position.
LOW
13:14
Sep 02
Sep 02
Author critiques MRNA's melanoma market size estimate versus RVMD's economics.
Author critiques MRNA's melanoma market size estimate versus RVMD's economics, framing it as a factual comparison rather than a trade call.
LOW
10:46
Sep 02
Sep 02
Author corrects the parent's claim about drug pricing negotiation direction without expressing.
Author corrects the parent's claim about drug pricing negotiation direction without expressing a personal trade position on the stock.
10:45
Sep 02
Sep 02
Author agrees with parent's defense of RVMD pricing but corrects that the sticker price is.
Author agrees with parent's defense of RVMD pricing but corrects that the sticker price is negotiated upward, not downward, without stating a position.
00:34
Sep 01
Sep 01
Revolution Medicines has expanding oncology opportunity.
Yee also likes Revolution Medicines. Its breakthrough pancreatic cancer drug is continuing to make a big impact in lung cancer, making it another major story and an attractive way to play the pharma innovation theme.
MED
03:50
Aug 27
Aug 27
Jefferies raises its price target on Revolution Medicines to 270 dollars from 242 dollars.
Jefferies raises its price target on Revolution Medicines to 270 dollars from 242 dollars, reflecting an updated valuation outlook.
21:04
Aug 26
Aug 26
FDA approval catalysts RVMD long.
FDA approval of daraxonrasib for pancreatic cancer is a fundamental catalyst; buy RVMD on regulatory win and clinical validation.
MED
20:09
Aug 26
Aug 26
Author highlights $475k annualized revenue at $39.5k per month just under buyside expectations.
Author highlights $475k annualized revenue at $39.5k per month just under buyside expectations, framing RVMD pricing as a positive catalyst.
16:08
Aug 26
Aug 26
Author compares street vs retail biotech top lists and notes RVMD approval with pricing.
Author compares street vs retail biotech top lists and notes RVMD approval with pricing expectations, but frames all names as observational research rather than personal positions.
LOW
15:21
Aug 26
Aug 26
FDA approval triggers RVMD congratulations
Congratulates RVMD management on FDA approval of pancreatic cancer drug; no explicit personal position or directional trade identified.
LOW
13:23
Aug 21
Aug 21
Consensus biotech longs round-trip as regrossing starts
Degrossing used these crowded biotech longs as the ATM to fund short covering; with regrossing already starting, gross rebuild should push these names back up as flows round-trip.
MED
09:57
Aug 21
Aug 21
A news wire reports a broad list of price target raises, cuts.
A news wire reports a broad list of price target raises, cuts, and coverage initiations across numerous stocks from various analysts, with no personal market view expressed.
09:59
Aug 20
Aug 20
Crowded longs will rebound after degrossing phase.
Expects crowded high-quality longs to catch a strong bid once hedge fund gross exposure rebuilds following the current degrossing phase.
MED
23:38
Aug 19
Aug 19
The author lists speculative biotech catalysts and best ideas by therapeutic area.
The author lists speculative biotech catalysts and best ideas by therapeutic area as research/watchlist content, not explicit current positions or forward calls.
23:36
Aug 19
Aug 19
Top biotech picks across various therapeutic areas
Author lists these biotech names as their best ideas across various therapeutic areas with the sector near all-time highs.
MED
13:09
Aug 17
Aug 17
Author shares a net conviction chart listing multiple biotech tickers without explicit position.
Author shares a net conviction chart listing multiple biotech tickers without explicit position language, so these are indexed as watch rather than directional calls.
LOW
12:58
Aug 17
Aug 17
Reports largest aggregate Q2 fund holdings
"Reports largest aggregate Q2 2026 holdings across 95 specialist funds based on 13F filings, no directional view."
MED
12:53
Aug 17
Aug 17
Reports widest ownership across specialist funds
"Reports widest Q2 2026 ownership across 95 specialist funds based on 13F filings, no directional view."
MED
12:50
Aug 17
Aug 17
Reports most reduced positions across funds
"Reports most reduced positions across specialist funds in Q2 2026 excluding M&A take-outs, no directional view."
MED
12:49
Aug 17
Aug 17
Reports most added positions across funds
"Reports most added positions across specialist funds from Q1 to Q2 2026, no directional view."
MED
12:31
Aug 17
Aug 17
Notes large aggregate Q2 fund holdings
Notes the stock is among the largest aggregate Q2 holdings across 93 funds based on 13F filings.
MED
12:12
Aug 17
Aug 17
The author lists battleground tickers without stating a position or directional view.
The author lists battleground tickers without stating a position or directional view, so they are indexed as watch only.
LOW
11:58
Aug 17
Aug 17
Reports widest Q2 ownership among specialist funds
Reports the widest Q2 2026 ownership across 93 specialist funds based on 13F filings.
MED
11:53
Aug 17
Aug 17
Reports most reduced positions by specialist funds
Reports the most reduced positions by specialist funds in Q2 2026, excluding M&A takeouts.
MED
11:50
Aug 17
Aug 17
Reports most added positions by specialist funds
Reports the most added positions by specialist funds from Q1 to Q2 2026.
MED
11:27
Aug 15
Aug 15
The author lists a massive basket of tickers without any directional commentary or position.
The author lists a massive basket of tickers without any directional commentary or position disclosure, so all are indexed as
LOW
11:02
Aug 11
Aug 11
RVMD NDA accepted; buy before approval premium
Buy RVMD ahead of NDA approval; daraxonrasib NDA accepted July 22 with priority review voucher, pan-RAS coverage across pancreatic and lung cancer — author explicitly warns it won't be cheaper post-approval, making it an attractive pre-approval M&A target.
MED
12:00
Aug 06
Aug 06
RVMD NDA accepted, cheaper pre-approval now
Buy RVMD ahead of daraxonrasib approval; NDA accepted July 22 with priority voucher, pan-RAS coverage across pancreatic and lung cancer creates urgency — author explicitly warns price rises post-approval, framing it as an M&A target for AZN.
MED
22:36
Aug 02
Aug 02
Rotating from ERAS into RVMD, cleaner story
Buy RVMD as a cleaner story preferred over ERAS; author is rotating capital from ERAS into RVMD imminently based on trusted conviction from others and a simpler investment thesis.
MED
16:52
Jul 27
Jul 27
Bullish on RVMD ahead of imminent FDA approval; aggressive pricing strategy and triplet.
Bullish on RVMD ahead of imminent FDA approval; aggressive pricing strategy and triplet ownership position should drive the stock above $200, with additional leverage as other companies need Darax for their own trials.
HIGH
About RVMD Analyst Coverage
Buzzberg tracks RVMD (Revolution Medicines) across 9 sources. 9 bullish vs 0 bearish calls from 9 analysts. Sentiment: predominantly bullish (20%). 44 total trade ideas tracked. Latest voices: A May MD, seedy19tron, Michael Yee.